Diomed Names William Allan Managing Director of UK Operation
31 Octobre 2006 - 4:02PM
Business Wire
Diomed Holdings, Inc. (AMEX:DIO), a leading developer and marketer
of minimally-invasive medical technologies, including its patented
EndoVenous Laser Treatment (EVLT�) for varicose veins, today
announced that it has appointed William D. Allan as Managing
Director of its wholly owned subsidiary, Diomed Ltd., Cambridge,
England effective November 1, 2006. In this role, Mr. Allan will be
responsible for planning, developing and implementing corporate
programs related to the management of Cambridge operations
including research and development, manufacturing, quality,
regulatory, finance, information technology, human resources,
global customer support and administration as well as sales and
marketing outside of the Americas. Prior to joining Diomed, Mr.
Allan spent fifteen years with Smith & Nephew in various
responsibilities including sales, marketing, business development
and general management. Most recently, he was Global Vice President
� Marketing for Smith & Nephew Wound Management with strategic
responsibilities for marketing through 33 countries. �We are
thrilled to have Bill join our executive management team,� stated
James Wylie, President & CEO of Diomed Holdings, Inc. �He is a
proven global healthcare professional with both capital and
consumable product experience. Importantly, Bill�s solid operating
experience combined with extensive sales and marketing experience
in Diomed�s targeted growth markets will help Diomed drive offshore
growth.� Mr. Allan studied Dental Surgery at the University of
Edinburgh and practiced as a Dental Surgeon in South Africa and in
the UK. He has an MBA from the University of Cape Town and AMP from
Insead Business School in Paris. Mr. Allan holds dual British and
South African citizenships. �I am very excited indeed to join
Diomed at this time,� commented Mr. Allan. �I look forward to
providing leadership to the UK and international business teams, as
we focus on driving sustainable growth and realizing the full
potential for the business.� About Diomed Diomed develops and
commercializes minimal and micro-invasive medical procedures that
use its proprietary laser technologies and disposable products.
Diomed�s EVLT� laser vein ablation procedure is used in varicose
vein treatments. Diomed also provides photodynamic therapy (PDT)
for use in cancer treatments, and dental and general surgical
applications. The EVLT� procedure and the Company�s related
products were cleared by the United States FDA in January of 2002.
Along with lasers and single-use procedure kits for its EVLT� laser
vein treatment, the Company provides its customers with state of
the art physician training and practice development support.
Additional information is available on the Company�s website:
www.evlt.com. EVLT� is a registered trademark of Diomed Inc.,
Andover, MA. Safe Harbor Safe Harbor statements under the Private
Securities Litigation Reform Act of 1995: Statements in this news
release looking forward in time involve risks and uncertainties,
including the risks associated with trends in the products markets,
reliance on third party distributors in various countries outside
the United States, reoccurring orders under OEM contracts, market
acceptance risks, technical development risks and other risk
factors. These statements relate to our future plans, objectives,
expectations and intentions. These statements may be identified by
the use of words such as "may," "will," "should," "potential,"
"expects," "anticipates," "intends," "plans," "believes" and
similar expressions. These statements are based on our current
beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties. Our actual results could differ
materially from those discussed in these statements. Our Annual
Report on Form SEC 10-KSB/A (the "Annual Report") contains a
discussion of certain of the risks and uncertainties that affect
our business. We refer you to the "Risk Factors" on pages 23
through 38 of the Annual Report for a discussion of certain risks,
including those relating to our business as a medical device
company without a significant operating record and with operating
losses, our risks relating to our commercialization of our current
and future products and applications and risks relating to our
common stock and its market value. Diomed disclaims any obligation
or duty to update or correct any of its forward-looking statements.
Diomed Holdings, Inc. (AMEX:DIO), a leading developer and marketer
of minimally-invasive medical technologies, including its patented
EndoVenous Laser Treatment (EVLT(R)) for varicose veins, today
announced that it has appointed William D. Allan as Managing
Director of its wholly owned subsidiary, Diomed Ltd., Cambridge,
England effective November 1, 2006. In this role, Mr. Allan will be
responsible for planning, developing and implementing corporate
programs related to the management of Cambridge operations
including research and development, manufacturing, quality,
regulatory, finance, information technology, human resources,
global customer support and administration as well as sales and
marketing outside of the Americas. Prior to joining Diomed, Mr.
Allan spent fifteen years with Smith & Nephew in various
responsibilities including sales, marketing, business development
and general management. Most recently, he was Global Vice President
- Marketing for Smith & Nephew Wound Management with strategic
responsibilities for marketing through 33 countries. "We are
thrilled to have Bill join our executive management team," stated
James Wylie, President & CEO of Diomed Holdings, Inc. "He is a
proven global healthcare professional with both capital and
consumable product experience. Importantly, Bill's solid operating
experience combined with extensive sales and marketing experience
in Diomed's targeted growth markets will help Diomed drive offshore
growth." Mr. Allan studied Dental Surgery at the University of
Edinburgh and practiced as a Dental Surgeon in South Africa and in
the UK. He has an MBA from the University of Cape Town and AMP from
Insead Business School in Paris. Mr. Allan holds dual British and
South African citizenships. "I am very excited indeed to join
Diomed at this time," commented Mr. Allan. "I look forward to
providing leadership to the UK and international business teams, as
we focus on driving sustainable growth and realizing the full
potential for the business." About Diomed Diomed develops and
commercializes minimal and micro-invasive medical procedures that
use its proprietary laser technologies and disposable products.
Diomed's EVLT(R) laser vein ablation procedure is used in varicose
vein treatments. Diomed also provides photodynamic therapy (PDT)
for use in cancer treatments, and dental and general surgical
applications. The EVLT(R) procedure and the Company's related
products were cleared by the United States FDA in January of 2002.
Along with lasers and single-use procedure kits for its EVLT(R)
laser vein treatment, the Company provides its customers with state
of the art physician training and practice development support.
Additional information is available on the Company's website:
www.evlt.com. EVLT(R) is a registered trademark of Diomed Inc.,
Andover, MA. Safe Harbor Safe Harbor statements under the Private
Securities Litigation Reform Act of 1995: Statements in this news
release looking forward in time involve risks and uncertainties,
including the risks associated with trends in the products markets,
reliance on third party distributors in various countries outside
the United States, reoccurring orders under OEM contracts, market
acceptance risks, technical development risks and other risk
factors. These statements relate to our future plans, objectives,
expectations and intentions. These statements may be identified by
the use of words such as "may," "will," "should," "potential,"
"expects," "anticipates," "intends," "plans," "believes" and
similar expressions. These statements are based on our current
beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties. Our actual results could differ
materially from those discussed in these statements. Our Annual
Report on Form SEC 10-KSB/A (the "Annual Report") contains a
discussion of certain of the risks and uncertainties that affect
our business. We refer you to the "Risk Factors" on pages 23
through 38 of the Annual Report for a discussion of certain risks,
including those relating to our business as a medical device
company without a significant operating record and with operating
losses, our risks relating to our commercialization of our current
and future products and applications and risks relating to our
common stock and its market value. Diomed disclaims any obligation
or duty to update or correct any of its forward-looking statements.
Diomed (AMEX:DIO)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Diomed (AMEX:DIO)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024